Arranta Bio Revenue and Competitors

Boston, MA USA

Location

$82M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Arranta Bio's estimated annual revenue is currently $29.8M per year.(i)
  • Arranta Bio's estimated revenue per employee is $193,750
  • Arranta Bio's total funding is $82M.

Employee Data

  • Arranta Bio has 154 Employees.(i)
  • Arranta Bio grew their employee count by -7% last year.

Arranta Bio's People

NameTitleEmail/Phone
1
Co-FounderReveal Email/Phone
2
Head Site OperationsReveal Email/Phone
3
VP - Head Information TechnologyReveal Email/Phone
4
Head Human Resources (VP)Reveal Email/Phone
5
SVP Business DevelopmentReveal Email/Phone
6
Head ProcurementReveal Email/Phone
7
Chief Financial OfficerReveal Email/Phone
8
Senior Director, Nucleic Acids- Process SciencesReveal Email/Phone
9
Associate Director, Engineering & Facilities OperationsReveal Email/Phone
10
Associate Director, Training & Document ManagementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Arranta Bio?

The Marvelous Microbiome The microbiome ? literally trillions of bacteria, fungi, protozoa and viruses living in and on the human body ? has been called the second genome. Over the last decade, there has been rapid acceleration in scientific understanding of its composition and functions. Today, around 200 companies are focused on understanding the human microbiome and its linkage to areas including infectious diseases and oncology to identify therapeutic targets. Arranta Bio is building a CDMO to support these innovators at the frontier of this exciting new sphere of medicine. Supporting the Pioneers of the Microbiome Arranta Bio is delivering on its vision to build the best-in-class microbiome contract development and manufacturing organization (CDMO) through our merger with a 10-year veteran CDMO, Captozyme, and the establishment of a commercial-ready manufacturing facility. We provide manufacturing and development support for live biotherapeutic products (LBPs) targeting gut health and microbiome-related diseases by providing development and manufacturing services that bring effective treatments to the market and patients in need. Microbiome CDMO Services Arranta Bio offers process development and cGMP manufacture of live biotherapeutic products (LBPs) for clinical and commercial supply. Partner With Us Whether you have a potential solution for the Next Big Thing in the microbiome or are curious about the powerful potential of LBPs, we're eager to hear from you. Contact us today by visiting our website: ArrantaBio.com

keywords:N/A

$82M

Total Funding

154

Number of Employees

$29.8M

Revenue (est)

-7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Arranta Bio News

2022-04-13 - VectorBuilder to spend $500M to construct gene therapy ...

In February, Recipharm bought two companies—Arranta Bio and Vibalogics—to build up its biologics offerings. Arranta specializes in microbiome therapeutic...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$34M15529%$273.8M
#2
$24.8M1607%N/A
#3
$24.8M1607%N/A
#4
$17.9M1635%N/A
#5
$33.3M1687%N/A